U.S. markets open in 4 hours 8 minutes

Vascular Biogenics Ltd. (VBLT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.3000-0.0400 (-2.99%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close1.3400
Open1.3100
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range1.2900 - 1.3700
52 Week Range0.9000 - 1.6400
Volume171,431
Avg. Volume600,818
Market Cap62.266M
Beta (5Y Monthly)0.80
PE Ratio (TTM)N/A
EPS (TTM)-0.5740
Earnings DateAug 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.85
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Earnings Preview: Vascular Biogenics (VBLT) Q2 Earnings Expected to Decline
    Zacks

    Earnings Preview: Vascular Biogenics (VBLT) Q2 Earnings Expected to Decline

    Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13

    TEL AVIV, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, August 13, 2020 at 8:30am Eastern Time to report second quarter ended June 30, 2020 financial results and to provide a corporate update. Thursday, August 13 @ 8:30amET From the US: 877-407-9208 International: 201-493-6784 Israel: 1 809 406 247 Conference ID: 13707066 Webcast: https://edge.media-server.com/mmc/p/y7tts2sv About VBL Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in a VBL-sponsored “all comers” phase 1 trial as well as in three VBL-sponsored tumor-specific phase 2 studies. Ofranergene obadenovec is currently being studied in a VBL-sponsored phase 3 potential registration trial for platinum-resistant ovarian cancer.INVESTOR CONTACT: Michael Rice LifeSci Advisors, LLC (646) 597-6979

  • Reuters

    MORNING BID-Fog, stall ... rally

    The views expressed are her own.) As U.S. coronavirus cases hit records and reopenings are dialled back, Federal Reserve officials admitted economic growth forecasts from the June policy meeting did not factor in the risk of a second wave. Fed Governor Lael Brainard summed it up as "a thick fog of uncertainty" and said "downside risks predominate." A similar message from the corporate world -- Delta Airlines CEO Ed Bastian said the industry was "at a stall right now."